No Data
No Data
Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Stifel cut
Fate Therapeutics Is Maintained at Neutral by HC Wainwright & Co.
Fate Therapeutics Is Maintained at Neutral by HC Wainwright & Co.
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Acumen Pharmaceuticals (ABOS) and DENTSPLY SIRONA (XRAY)
Fate Therapeutics: Advancements and Differentiation in Autoimmune and Cancer Therapies Support Buy Rating
Express News | Fate Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $5 From $7
Stifel Nicolaus Sticks to Their Hold Rating for Fate Therapeutics (FATE)